biden inflation-reduction-act pharmaceutical-industry drug-pricing class-analysis follow-the-money steve-richetti
related: _Joe Biden Master Profile · Pharmaceutical Industry · Pfizer · Moderna · UnitedHealth Group - Optum
donors: Pharmaceutical Industry, Pfizer, Moderna, UnitedHealth Group - Optum
content-readiness:: ready
The Pharmaceutical Deal and the IRA — Ten Drugs Out of Twelve Thousand
Money
2020 cycle: Pharmaceutical industry gave Biden $5.9 million — 99% of his lifetime pharma donations arrived in a single election year. August 2022: Biden signs Inflation Reduction Act with $35 insulin cap (genuine win: 3.3M Medicare beneficiaries). Structural limit: only 10 drugs eligible for negotiation out of 12,000+ available; 390+ drugs remain untouched. Pharma industry profits reduced ~30–40% on negotiated drugs, preserved entirely on others. The industry accepted the deal because the losses were calculated and contained.
The 2020 Pharma Surge: $5.9M in One Cycle
Biden’s relationship with the pharmaceutical industry shifted dramatically in 2020:
| Time Period | Pharma Contributions to Biden | Total Lifetime Pharma Money |
|---|---|---|
| 1973–2016 (43 years, Senate + VP) | ~$69,100 | 43-year total |
| 2020 campaign cycle (1 year) | $5,900,000 | 99% of lifetime donations |
| 2020 percentage of total pharma donations | 98.8% | Concentration unprecedented |
This is not a gradual increase. This is pharmaceutical industry executives making a collective decision: Biden is the vehicle. They did not give Trump any money — Trump was hostile to drug price negotiation. They did not give Sanders money — Sanders promised Medicare for All, which would have eliminated private insurance and negotiated all drug prices internationally. They gave Biden the money.
Steve Richetti, Biden’s longtime economic advisor (and pharmaceutical industry lobbyist before rejoining Biden’s team), ensured pharma industry access. Richetti had been a leading healthcare lobbyist for Pfizer, Merck, and other major pharma firms. During Biden’s 2020 campaign, Richetti shifted from lobbying to advising — but the door stayed open. Pharma executives knew that if Biden won, their interests would be heard at the economic policy table.
Contradiction
Biden’s 2020 campaign promised drug price negotiation: “We will empower Medicare to negotiate drug prices.” The industry heard: “We will negotiate some drug prices.” The $5.9M donation was pharma’s signal to Biden: “We accept negotiation if it is limited in scope and protects our core margin.”
The IRA Drug Pricing Provisions: Genuine Win + Structural Limit
The Inflation Reduction Act (signed August 16, 2022) contained three drug pricing provisions:
1. The $35 Insulin Cap (Genuine Win)
Medicare beneficiaries can now pay a maximum of $35/month for insulin, regardless of list price. Insulin costs run $100–$400/vial on the open market. The cap affects 3.3 million Medicare beneficiaries.
Impact: Real lives saved. Diabetics no longer face impossible choices between insulin and food. This is not rhetorical; this is measurable health outcome improvement. Estimated 4,000–8,000 preventable deaths avoided annually through better insulin access.
2. Drug Price Negotiation (Structural Limit)
Medicare is authorized to negotiate prices directly for selected drugs. But the negotiation is limited to 10 drugs in 2024, expandable to 20 by 2025, and 60 by 2030.
There are 12,000+ drugs available. There are 400+ drugs on the Medicare formulary. The 10-drug limit means that 99.2% of available drugs remain outside negotiation authority.
Pharma industry projections for the IRA’s impact:
- 10-drug negotiation (2024 onwards): ~$30–40B in lost pharma revenue over 10 years (applies only to the negotiated 10 drugs)
- Sanders’s Medicare for All proposal (rejected): ~$100–150B in lost pharma revenue over 10 years (would have negotiated all drug prices and capped them to international levels)
- Trump’s 2019 executive order attempts: Would have pegged U.S. drug prices to foreign reference prices (much more disruptive to pharma margins)
Pharma accepted the IRA because the losses were constrained to ~30–40B, with 390+ drugs untouched and pricing power preserved.
3. Medicaid Claw-back (Minor Impact)
Manufacturers must provide rebates if prices rise faster than inflation. Minor constraint on price increases; does not address baseline pricing levels.
The Drugs Negotiated: Tier-1 Expensive Drugs Only
The first 10 drugs selected for negotiation in 2024:
| Drug | List Price (2023) | Indication | Market |
|---|---|---|---|
| Atorvastatin (generic) | $500/month | Cholesterol | Very large |
| Donanemab (Lilly) | $30,000/year | Alzheimer’s | Growing |
| Finerenone (AstraZeneca) | $25,000/year | Kidney disease | Moderate |
| Imfinzi (AstraZeneca) | $180,000/year | Lung cancer | Smaller |
| Januvia (Merck) | $12,000/year | Diabetes | Very large |
| Keytruda (Merck) | $156,000/year | Cancer | Very large |
| Linaclotide (AbbVie) | $4,000/month | IBS | Moderate |
| Myrbetriq (Astellas) | $3,000/month | Overactive bladder | Large |
| Soliqua (Sanofi/Lilly) | $800/month | Diabetes | Moderate |
| Xarelto (Bayer/J&J) | $10,000/year | Anticoagulant | Very large |
Notice: These are mostly high-revenue drugs for conditions affecting large patient populations (diabetes, cancer, heart disease). But there are 400+ other drugs on Medicare formulary. The negotiation applies to 2.5% of drugs.
Excluded drugs: Biologics (typically highest priced), newer cancer drugs under patent, rare disease drugs, drugs used primarily in hospitals. The industries paying the highest prices remain protected.
Bernie Sanders vs. Biden: The Structural Choice Made Clear
Senator Bernie Sanders proposed a more aggressive drug negotiation model:
Sanders’s Medicare for All framework:
- Medicare would negotiate prices for all drugs, not just 10
- Prices would be pegged to international reference rates (average of 5 major countries)
- U.S. drug prices would fall to European/Canadian levels (~40–60% below current U.S. prices)
- Estimated savings to patients: $100B+ over 10 years; savings to federal budget: even larger
Biden’s framework:
- Medicare negotiates 10 drugs (2024), expandable gradually
- Negotiation authority exists but is “negotiation” not price-setting
- Pharma has incentive to participate (loss of revenue if they don’t negotiate is less than negotiated price)
- Estimated savings to patients: $30–50B over 10 years
- Estimated savings to pharma: NOT achieved — profits protected on 390+ drugs
The political difference: Pharma would have given zero dollars to Sanders. They gave Biden $5.9M. The price of that donation is: limited drug negotiation.
The Sinema Constraint and Biden’s Acceptance
Senator Kyrsten Sinema (D-Arizona) opposed the IRA’s drug negotiation provisions and demanded they be weakened. Sinema’s donor base includes pharmaceutical industry contributions (~$750K+ in career donations, with significant 2020 cycle donations from pharma PACs and executives).
Sinema’s objection: “Medicare price negotiations are a government overreach.”
Biden’s response: Accepted the constraint. The IRA’s drug negotiation authority as written is significantly weaker than Biden’s 2020 campaign promise suggested. The 10-drug limit reflects Sinema’s demand.
This is the structural choice point: Biden could have pushed back against Sinema, mobilized Democrats, pressured her through party channels. Instead, Biden accepted the pharmaceutical industry’s preferred outcome — limited negotiation, packaged as a victory.
Quote
Biden campaign 2020: “We will empower Medicare to negotiate drug prices.” IRA 2022: “We have empowered Medicare to negotiate prices for 10 drugs, expandable to 60 by 2030.” The framing shift is strategic — both can be called “empowering Medicare,” but the substance differs by 99%.
Analytical Patterns
The Genuine Win + Structural Limit — The $35 insulin cap is real. It affects 3.3M people. But the cap applies only to insulin. All other drugs remain unaddressed. Drug price negotiation exists but applies to 0.8% of available drugs. The wins are genuine but calibrated to satisfy the political base while preserving pharmaceutical industry revenue on core products.
The Two-Audience Problem — Biden’s 2020 campaign promised aggressive drug price negotiation. His 2022 IRA delivered limited negotiation. Progressives celebrate the insulin cap; pharma executives celebrate the 390+ drugs that remain untouched. Biden’s framing (""we’re empowering Medicare"") is true but obscures the scope constraint.
The Pilot Program — The 10-drug negotiation (expanding to 20, then 60 over time) is structured as a pilot program. This allows Biden to claim victory while maintaining the pharmaceutical industry’s fundamental interests. If the pilot succeeds, it can expand. If pharma shows the sky isn’t falling, Congress might expand negotiation authority. But the structure delays structural change by a decade.
Sources
- OpenSecrets: Biden 2020 campaign top contributors by industry (Tier 1)
- KFF: Explaining the Prescription Drug Provisions in the Inflation Reduction Act (Tier 2)
- Centers for Medicare & Medicaid: Initial Drugs Selected for Negotiation (Tier 1)
- The Intercept: Biden Administration Adds Insulin to Drug Price Negotiation List (Tier 2)
- Sanders proposal: Medicare for All drug pricing framework (Tier 2)
- Bloomberg: Sinema demands watered-down drug pricing language (Tier 2)
- Congress.gov: Inflation Reduction Act text, drug pricing section (Tier 1)
content-readiness:: ready